Application

Anti-PDE2A, Cat. No. ABN1486, is a highly specific rabbit polyclonal antibody that targets cGMP-dependent 3′,5′-cyclic phosphodiesterase and has been tested in Immunohistochemistry (Paraffin) and Western Blotting.

Research CategoryNeuroscience

Immunohistochemistry Analysis: A 1:1,000 dilution of this antibody detected PDE2A in human cerebellum, human cerebral cortex, human skin, human lung, human kidney, and human heart tissues.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

cGMP-dependent 3′,5′-cyclic phosphodiesterase (UniProt: O00408; also known as EC:3.1.4.17, PDE2A, Cyclic GMP-stimulated phosphodiesterase, CGS-PDE, cGSPDE) is encoded by the PDE2A gene ( Gene ID: 5138) in human. PDE2A is an evolutionarily conserved cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP that are key regulators of many important physiological processes. PDE2A is expressed in both the periphery and in the central nervous system, however its expression is highest in the brain, where it is mainly localized in the cortex, hippocampus, and striatum. Three splice variants of PDE2A have been described, the PDE2A1, PDE2A2 and PDE2A3. PDE2A1 is cytosolic whereas -A2 and -A3 are membrane bound. PDE2A isoform 2 is specifically targeted to the mitochondrial matrix, where it forms a local signaling system with soluble adenylate cyclase regulating the respiratory chain. PDE2A is a dimeric enzyme that binds 2 divalent metal cations per subunit. Site 1 may preferentially bind zinc ions, while site 2 has a preference for magnesium and/or manganese ions. Each PDE2A monomer contains an N-terminal (200 residues) domain of unknown function, tandem GAF domains (GAF A and GAF B), and a C-terminal catalytic domain. GAF A functions as a dimerization locus. PDE2 A catalytic activity is allosterically stimulated by cGMP binding to its GAF B domain. Binding of cGMP induces conformational change in the protein structure leading to higher enzyme activity. Ref.: Acin-Perez, R., et al. (2011). J. Biol. Chem. 286 (35): 30423-30432; Martinez, SE., et al. (2002). Proc. Natl. Acad. Sci. USA 99(20); 13260-13265; Trabanco, A., et al. (2016). Expert Opin. Therap. Patents 26(8): 933-946).

Immunogen

KLH-conjugated linear peptide corresponding to 17 amino acids from the N-terminal region of human PDE2A.

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Purified rabbit polyclonal antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Affinity Purified

Quality

Evaluated by Western Blotting in human cerebral cortex tissue lysate.

Western Blotting Analysis: 1 µg/mL of this antibody detected PDE2A in 10 µg of human cerebral cortex tissue lysate.

Specificity

This polyclonal antibody specificaaly detects PDE2A in human.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Target description

~106 kDa observed; 105.72 kDa calculated. Uncharacterized bands may be observed in some lysate(s).